Search the Newsreel

Lake Street Maintains Pulmonx(LUNG.US) With Buy Rating, Maintains Target Price $4

Lake Street has reiterated its Buy rating for Pulmonx (LUNG.US) and maintained its price target at $4. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Pulmonx Stock Rises On Narrowed Q2 Losses, Margin Gains

(RTTNews) - Pulmonx Corporation (LUNG), a medical device company focused on minimally invasive treatments for lung disease, yesterday announced financial results for the second quarter ended June 30, 2026, showing lower revenue compared to the same period last year but improved margins and reduced …

Hang Lung Properties: Revenue up 23% to HK$6.1B; underlying net profit down 10% amid higher sales losses

Hong Kong's Hang Lung Properties H1 revenue rises on higher occupancy

Pulmonx Affirms FY26 Sales Guidance of $90.000M-$92.000M

Pulmonx (NASDAQ: LUNG) has reiterated its full-year 2026 sales guidance, keeping the range at $90.000 million to $92.000 million. This guidance is consistent with previous statements and aligns closely with the consensus analyst estimate of $90.832 million. The affirmation signals management's confidence in the …

Pulmonx Corp Q2 revenue falls, but beats estimates

Pulmonx Corp's Q2 revenue experienced a decline but still managed to surpass analyst estimates. The article, sourced from Reuters via TradingView News, provides a brief update on the company's financial performance.

Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates

Pulmonx Corporation (LUNG) reported a Q2 loss of $0.24 per share, surpassing the Zacks Consensus Estimate of a $0.28 loss, and also beat revenue expectations with $22.76 million. Despite underperforming the market year-to-date, the company has consistently topped revenue estimates in the past four …

Pulmonx Reports Second Quarter 2026 Financial Results

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2026 ended June 30, 2026. Recent Highlights Achieved …

BlackRock (LUNG) updates Pulmonx Corp stake, reports 765,721 shares owned

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 765,721 shares of Pulmonx Corp (LUNG) common stock, which represents 1.8% of the class. BlackRock holds sole voting and sole dispositive power over all these shares, with no shared power. The …

Lung Fung Group Holdings Limited: Target Price Consensus and Analysts Recommendations | 2290 | KYG5701W1033

Pulmonx Q2 Earnings Call Highlights

Key Points Interested in Pulmonx Corporation? Here are five stocks we like better. Pulmonx reported $22.8 million in Q2 revenue, down 5% year over year, but U.S. revenue rose 7% sequentially as the company rebuilt its sales force and added 12 treating centers. Management …

Pulmonx (NASDAQ:LUNG) Announces Earnings Results

Earnings call transcript: Pulmonx tops Q2 2026 estimates, shares jump 14.4%

Pulmonx Corp. Revenue Breakdown – LSX:A2P1AF

Pulmonx Corp. (LSX:A2P1AF) generated €77.05 million in revenue last year, primarily from its Interventional Pulmonology segment. The United States was the largest contributor to revenue, accounting for €48.55 million in the past year. This report provides a breakdown of the company's financial performance by …

Pulmonx's Aug. 11 Boston fireside chat will be webcast live

Pulmonx (Nasdaq: LUNG) announced it will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET. A live and archived webcast of the event will be …

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

Pulmonx Corporation will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. The event, taking place in Boston, will also be accessible via a live and archived webcast on the "Investors" section of the company's website. …

LUNG|Pulmonx Corp|Price:1.225|Chg%:+0.055

This article from TradingKey provides a comprehensive stock analysis of Pulmonx Corp (LUNG), highlighting its relatively healthy fundamentals, significant growth potential, and "fairly valued" status within the Healthcare Equipment & Supplies industry. It notes high institutional ownership and recent "Buy" ratings from analysts with …

Pulmonx Corp (LUNG) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Pulmonx Corp (LUNG), listing its major shareholders and their proportions, as well as categorizing shareholder types. It also provides institutional shareholding data over several quarters and recent shareholder activity. Additionally, the article lists related ETFs that include …

Pulmonx Corp expected to post a loss of 28 cents a share - Earnings Preview

Pulmonx Corp (NASDAQ: LUNG) is anticipated to report a loss of 28 cents per share in its upcoming earnings announcement. This information, provided by Refinitiv, suggests the company is facing an expected negative financial outcome for the period.

Salungano Group Limited Revenue Breakdown – JSE:SLG

Pulmonx Market Sentiment

This article analyzes the market sentiment for Pulmonx (LUNG) based on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from 9 analysts with an average price target of $8, a 3.2% short float, and no recent insider activity. …

Pulmonx Corp. Revenue Breakdown – MUN:4NI

This article provides a revenue breakdown for Pulmonx Corp. (MUN:4NI), showing that its top-performing segment, Interventional Pulmonology, generated €77.05 million last year, down from €80.94 million in the prior year. The United States was the greatest contributor, accounting for €48.55 million, a decrease from …

Pulmonx Corp (LUNG) Cash Flow

This article provides a detailed cash flow statement for Pulmonx Corp (LUNG), including operating, investing, and financing cash flows presented quarterly and annually. It outlines key financial metrics and offers definitions for different types of cash flow, along with Pulmonx Corp's specific figures for …

Pulmonx (LUNG) Q1 2026 Earnings: Narrow EPS Beat Sends Stock Lower by 4.1% - CEO Earnings Statement

Pulmonx Corp (LUNG) Financial Health: Profitability & Balance Sheet Analysis

The article provides a financial health analysis of Pulmonx Corp (LUNG), noting its current financial score of 6.77, ranking 133rd in the Healthcare Equipment & Supplies industry. It highlights a stable financial status but low operating efficiency, with recent quarterly revenue decreasing by 8.66% …

Pulmonx Corp (LUNG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Pulmonx Corp (LUNG), focusing on its regional revenue contributions. As of the specified date, the company has not yet disclosed detailed data for business segments or specific quarterly financial years. The primary revenue source is the United …

Pulmonx Corp (LUNG) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Pulmonx Corp (LUNG) focusing on its dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent payouts. The article includes current stock pricing and market …

TradingKey

This article provides a detailed quarterly and annual income statement for Pulmonx Corp (LUNG), offering financial insights into its revenue, operating expenses, and net income. It also includes frequently asked questions about interpreting income statements and key metrics for analyzing LUNG stock. The data …

Pulmonx Corp (LUNG) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Pulmonx Corp (LUNG), noting its current valuation score of 7.71, which ranks 138 out of 200 in the Healthcare Equipment & Supplies industry. The company's P/E ratio is reported as -0.91, and other key valuation metrics like …

LUNG|Pulmonx Corp|Price:1.220|Chg%:+0.010

Pulmonx Corp (LUNG) closed at 1.170 USD, down 4.10%. The company, a commercial-stage medical technology firm specializing in COPD treatments, shows strong fundamentals and significant growth potential despite a recent weak stock market performance. Analysts rate it a "Buy" with a target price of …

Pulmonx (LUNG) Projected to Release Earnings on Wednesday

Pulmonx Sets July 29 Webcast to Discuss Second-Quarter Results

Confined to Hong Kong, Lung Fung lacks tonic for growth-hungry investors

Pulmonx Q1 2026 Earnings: EPS Beat Drives 7.55% Stock Surge - Trough Earnings Signal

LUNG Q1 2026 Earnings: EPS Beats Estimates by Narrow Margin, Shares Rise - Book Value Growth

Deloitte China assists the listing of Lung Fung Group on SEHK